These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

164 related articles for article (PubMed ID: 10974399)

  • 1. Therapeutic effect of 1 M tegafur-0.4 M 5-chloro-2, 4-dihydroxypridine-1 M potassium oxonate (S-1) on head and neck squamous carcinoma cells.
    Nishimura G; Yanoma S; Mizuno H; Satake K; Taguchi T; Ikeda Y; Tsukuda M
    Cancer Lett; 2000 Oct; 159(1):1-7. PubMed ID: 10974399
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Therapeutic effect of 1 M tegafur-0.4 M 5-chloro-2,4-dihydroxypyridine-1 M potassium oxonate (S-1) on liver metastasis of xenotransplanted human colon carcinoma.
    Konno H; Tanaka T; Baba M; Kanai T; Matsumoto K; Kamiya K; Nakamura S
    Jpn J Cancer Res; 1999 Apr; 90(4):448-53. PubMed ID: 10363584
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Preclinical antitumor efficacy of S-1: a new oral formulation of 5-fluorouracil on human tumor xenografts.
    Fukushima M; Satake H; Uchida J; Shimamoto Y; Kato T; Takechi T; Okabe H; Fujioka A; Nakano K; Ohshimo H; Takeda S; Shirasaka T
    Int J Oncol; 1998 Oct; 13(4):693-8. PubMed ID: 9735397
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Antitumor activity of 1 M tegafur-0.4 M 5-chloro-2,4-dihydroxypyridine-1 M potassium oxonate (S-1) against human colon carcinoma orthotopically implanted into nude rats.
    Shirasaka T; Nakano K; Takechi T; Satake H; Uchida J; Fujioka A; Saito H; Okabe H; Oyama K; Takeda S; Unemi N; Fukushima M
    Cancer Res; 1996 Jun; 56(11):2602-6. PubMed ID: 8653704
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Adjuvant chemotherapy with S-1 after curative chemoradiotherapy in patients with locoregionally advanced squamous cell carcinoma of the head and neck: Reanalysis of the ACTS-HNC study.
    Kubota A; Nakatani E; Tsukahara K; Hasegawa Y; Takemura H; Terada T; Taguchi T; Nagahara K; Nakatani H; Yoshino K; Higaki Y; Iwae S; Beppu T; Hanamure Y; Tomita K; Kohno N; Kawabata K; Teramukai S; Fujii M;
    PLoS One; 2018; 13(6):e0198391. PubMed ID: 29883463
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Antitumor activity and low intestinal toxicity of S-1, a new formulation of oral tegafur, in experimental tumor models in rats.
    Takechi T; Nakano K; Uchida J; Mita A; Toko K; Takeda S; Unemi N; Shirasaka T
    Cancer Chemother Pharmacol; 1997; 39(3):205-11. PubMed ID: 8996521
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Invention of a tumor-selective 5-fluorouracil derivative named S-1 by biochemical modulation of 5-fluorouracil].
    Shirasaka T; Shimamoto Y; Kato T; Fukushima M
    Gan To Kagaku Ryoho; 1998 Feb; 25(3):371-84. PubMed ID: 9492831
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Early phase II study of S-1 in patients with advanced head and neck cancer. S-1 Cooperative Study Group (Head and Neck Working Group)].
    Inuyama Y; Kida A; Tsukuda M; Kohno N; Satake B
    Gan To Kagaku Ryoho; 1998 Jul; 25(8):1151-8. PubMed ID: 9679577
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Immunotoxic effects of a new antineoplastic agent S-1 in mice--comparison with S-1, UFT and 5-FU].
    Kouchi Y; Maeda Y; Morinaga H; Ohuchida A
    J Toxicol Sci; 1996 Nov; 21 Suppl 3():691-701. PubMed ID: 9021669
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [New oral anticancer drug, TS-1 (S-1)--from bench to clinic].
    Shirasaka T; Tsukuda M; Inuyama Y; Taguchi T
    Gan To Kagaku Ryoho; 2001 Jun; 28(6):855-64. PubMed ID: 11432358
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Combined effects of the oral fluoropyrimidine anticancer agent, S-1 and radiation on human oral cancer cells.
    Harada K; Kawaguchi S; Supriatno ; Onoue T; Yoshida H; Sato M
    Oral Oncol; 2004 Aug; 40(7):713-9. PubMed ID: 15172641
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Clinical efficacy of administration with S-1 alone for head and neck carcinoma].
    Tsukuda M; Ishitoya J; Mikami Y; Matsuda H; Katori H; Horiuchi C; Taguchi T; Yoshida T; Toth G
    Gan To Kagaku Ryoho; 2006 Jun; 33 Suppl 1():144-9. PubMed ID: 16897991
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Superior antitumour activity of S-1 in tumours with a high dihydropyrimidine dehydrogenase activity.
    Fujiwara H; Terashima M; Irinoda T; Takagane A; Abe K; Nakaya T; Yonezawa H; Oyama K; Takahashi M; Saito K; Takechi T; Fukushima M; Shirasaka T
    Eur J Cancer; 2003 Nov; 39(16):2387-94. PubMed ID: 14556932
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Pharmacokinetics of S-1, an oral formulation of ftorafur, oxonic acid and 5-chloro-2,4-dihydroxypyridine (molar ratio 1:0.4:1) in patients with solid tumors.
    Peters GJ; Noordhuis P; Van Kuilenburg AB; Schornagel JH; Gall H; Turner SL; Swart MS; Voorn D; Van Gennip AH; Wanders J; Holwerda U; Smid K; Giaccone G; Fumoleau P; Van Groeningen CJ
    Cancer Chemother Pharmacol; 2003 Jul; 52(1):1-12. PubMed ID: 12739060
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The modulated oral fluoropyrimidine prodrug S-1, and its use in gastrointestinal cancer and other solid tumors.
    Anticancer Drugs; ; . PubMed ID: 15075664
    [TBL] [Abstract][Full Text] [Related]  

  • 16.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 17.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 18.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 19.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 20.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 9.